pharmaceuticals
Novartis plans to cut 2,100 jobs in Switzerland, Britain
Swiss pharmaceuticals giant hopes to lower its overall headcount worldwide to below 100,000, from about 126,000 today.
-
Freeland to return to NAFTA talks in Washington this week
Intense discussions continue but stalling over dispute settlement mechanism.
Valeant invests $10M in Laval plant upgrades
Enhances manufacturing capabilities and export capacity.
Valeant invests $8M in Manitoba manufacturing plant
Company to transfer North American production of Xifaxan and Apriso to Steinbach facility.
Lawyer pushing Cold fX class action is ‘manufacturing’ case: Valeant
Pharmaceutical firm’s lawyer cites an absence of an easily defined class of complainants.
Cold-fX case should receive class action approval: lawsuit
Makers accused of misleading the public about remedy’s short-term effectiveness.
Overnight suspense over TPP, on verge of completion
Trade deal stalled over next-gen pharmaceuticals that delayed resolution of other issues.
Canada Drugs faces US charges for counterfeit drugs
Online pharmacy based in Winnipeg accused of smuggling, money laundering and conspiracy.
CETA to increase drug costs by up to $1.65B
Analysts says delaying the arrival of cheaper generic drugs will add up to 13%.
BC Supreme Court allows class action over anti-obesity drug Meridia
Suit to involve makers of the drug, Abbott Laboratories and generic manufacturer Apotex.
Foreign companies in China feel unfairly singled out by government probes
European Chamber of Commerce in China says accusations get more publicity from state-controlled media.
Modest growth forecast for five key industry sectors
Conference Board of Canada, BDC report says companies are looking for new markets
Key industries waiting on customers for full recovery
Canadian manufacturers in key industry sectors are waiting for their customers to fully recover from the recession before consistent growth will occur, says a Conference Board of Canada report.
